Point Of Care Diagnostic MarketSize, Share & Industry Analysis, 2026-2034By TechnologyBy ProductBy End-useBy Sample TypeBy Distribution Channel

Point-of-care diagnostics are testing devices and assay systems designed to deliver a result at or near the site of patient care, rather than requiring a sample to be sent to a central laboratory. The category spans handheld meters, cartridge-based analyzers, lateral flow strips and benchtop instruments used to measure analytes such as glucose, infectious disease markers, cardiac and coagulation parameters, and hormones. Buyers include hospitals, physician offices, retail and urgent care clinics, public health programs and increasingly patients themselves testing at home.

Growth of 8.21% a year carries the global point of care diagnostic market from USD 28.5 billion in 2025 to USD 56.74 billion in 2034. The full series behind that rate covers USD 24.1 billion in 2020, USD 27.8 billion in 2024, USD 30.2 billion in 2026 and USD 41.4 billion in 2030, with 2025 as the base year.

On the technology axis, growth rates run from 5.88% for Lateral Flow Assays up to 11.62% for Molecular/PCR-based POC. Lateral Flow Assays carries the volume: USD 9.69 billion and 34% of revenue in 2025, USD 15.89 billion and 28% in 2034. Share moves toward Biosensor-based Platforms, Molecular/PCR-based POC and Microfluidics-based Platforms and away from Lateral Flow Assays and Immunoassay-based Platforms, though no line shrinks in revenue terms.

By product, Glucose Testing accounts for 18.81% of 2025 revenue at USD 5.36 billion, reaching USD 9.65 billion and 17.01% by 2034. HPV POC grows faster at 14.2% against 6.75%, moving from 1.51% of revenue to 2.5% by 2034. This axis divides the same revenue as the technology split instead of adding to it, so the two are read together and never summed.

North America is the largest region at 38% of 2025 revenue, worth USD 10.83 billion and reaching USD 19.29 billion by 2034. Asia Pacific follows at 26%, moving from USD 7.41 billion to USD 18.17 billion, and Middle East and Africa is the smallest at 6%. Asia Pacific gain share across the period, so growth is not distributed evenly between regions.

The 2025 total is triangulated from published sources and category proxies, with no independently sourced count behind it. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, five technology lines and five segmentation axes across a fifteen-year window.

• A forecast-period rate of 8.21% takes the market from USD 28.5 billion in 2025 to USD 56.74 billion in 2034, against 3.41% recorded over the 2020-2025 historical period.
• 34% of 2025 revenue sits in Lateral Flow Assays (USD 9.69 billion) and it remains the largest technology line in 2034 at USD 15.89 billion and 28%.
• Molecular/PCR-based POC is the fastest-growing line at 11.62%, lifting its share from 15% in 2025 to 20% in 2034 and its revenue from USD 4.28 billion to USD 11.35 billion.
• The bull case puts 2034 revenue at USD 64.12 billion and the bear case at USD 49.65 billion, either side of the USD 56.74 billion base case, each with its own stated assumption in the full report.
• 38% of 2025 revenue is generated in North America, worth USD 10.83 billion and rising to USD 19.29 billion by 2034; Middle East and Africa is smallest at 6%.
• 85% of North America's base-year revenue comes from the United States alone: USD 9.21 billion in 2025, rising to USD 16.4 billion by 2034, which is why it is that region's worked example.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

The global point of care diagnostic market is shaped over 2026-2034 by three measurable movements: a change in the technology mix, a shift in where revenue sits geographically, and the 8.21% rate carrying the total.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; what separates them is which takes the larger part of the growth.

Composition shifts on the technology axis. 11.62% against 5.88%: that gap, between Molecular/PCR-based POC and Lateral Flow Assays, is the largest on the technology axis. Shares follow: 15% to 20% for Molecular/PCR-based POC, 34% to 28% for Lateral Flow Assays. Revenue rises on both sides; USD 4.28 billion to USD 11.35 billion and USD 9.69 billion to USD 15.89 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

Regional weight shifts toward Asia Pacific. Asia Pacific moves from 26% of revenue in 2025 to 32% in 2034, worth USD 7.41 billion rising to USD 18.17 billion. Share moves off the others in turn: North America at 38% moving to 34%, Europe at 24% moving to 22%, Latin America at 6% moving to 6%, Middle East and Africa at 6% moving to 6%, each still growing in revenue terms. Revenue added in this market is therefore concentrating geographically instead of spreading evenly, and a participant weighted toward a share-losing region grows more slowly than the market even while its own revenue climbs.

The series never breaks trajectory. Fifteen years of revenue run USD 24.1 billion in 2020, USD 27.8 billion in 2024, USD 28.5 billion in 2025, USD 30.2 billion in 2026, USD 41.4 billion in 2030 and USD 56.74 billion in 2034. The forecast rate of 8.21% sits against 3.41% over the historical period, so the projection extends an observed trend instead of proposing a new one. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the technology and regional axes, not by the headline rate.

Growth is concentrated in Molecular/PCR-based POC

Three sources account for the growth to 2034: 8.21% compounding across the base, share moving toward the faster technology lines, and above-market expansion in the leading regions.

The bear case and what drives it

Upside case: USD 64.12 billion by 2034

Concentration on the technology axis

USD 10.83 billion of 2025 revenue is generated in North America, 38% of the global point of care diagnostic market and reaches USD 19.29 billion by 2034. It is a dominant region on this axis, first by revenue throughout the period.

Share settles at 34% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Within the region the technology split tracks the global one; 34% of 2025 revenue in Lateral Flow Assays, fastest growth of 11.62% in Molecular/PCR-based POC. Per-axis and per-country detail for North America sits in the full report.

The United States is the largest market within North America, generating USD 9.21 billion in 2025 and projected to reach USD 16.4 billion by 2034. Carrying 85% of the region in the base year, it sets North America's direction instead of merely contributing to it. Set against USD 10.83 billion and USD 19.29 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

The technology pattern in the United States is the global one: 34% of 2025 revenue in Lateral Flow Assays, 28% by 2034, against 11.62% growth in Molecular/PCR-based POC taking it from 15% to 20%. Since 85% of North America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Revenue by technology for the United States is reported separately in the full report.

Point of care diagnostic devices sold in the United States fall under the Food and Drug Administration's medical device framework, specifically as in vitro diagnostics regulated through the Center for Devices and Radiological Health. Most point of care assays are classified based on the risk they pose to patient safety and the complexity of the testing involved, which determines whether a submission requires premarket notification, premarket approval, or qualifies for a lower-tier exemption. Devices used outside a traditional laboratory setting are also evaluated for waived-testing status under the Clinical Laboratory Improvement Amendments, a separate but connected framework governing where and by whom a test may be run. Manufacturers must maintain quality system compliance, accurate labelling describing intended use and limitations, and clearance documentation before commercial distribution begins.

Competition in the United States runs between the suppliers this study tracks: F. Hoffmann-La Roche Ltd., Danaher, BD, Qiagen, Abbott, Siemens Healthcare AG, bioMerieux SA, Zoetis, Inc., Instrumentation Laboratory, Nova Biomedical, Quidel Corp., Trividia Health, Inc., Sekisui Diagnostics, Nipro Corp., Trinity Biotech, Orasure Technologies, Inc. and Spectral Medical, Inc.. Volume sits in Lateral Flow Assays at 34% of 2025 revenue; movement sits in Molecular/PCR-based POC at 11.62% growth. Per-company positioning and share at country level are in the full report only.

Within North America, Canada accounts for 15% of regional revenue and 5.68% of the global total, worth USD 1.62 billion in 2025 and USD 2.89 billion by 2034.

In Europe, 24% of global revenue puts 2025 at USD 6.84 billion with USD 12.48 billion projected for 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

By 2034 the share stands at 22%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Lateral Flow Assays leads here as it does globally, at 34% of 2025 revenue, and Molecular/PCR-based POC again grows fastest at 11.62%. Europe is reported axis by axis and country by country in the full study.

The largest single market in Europe is Germany, at USD 1.85 billion in 2025 and USD 3.37 billion in 2034. At 27% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. The region itself runs USD 6.84 billion to USD 12.48 billion over the same period, and this is the market carrying the country-level detail in the full report.

The technology pattern in Germany is the global one: 34% of 2025 revenue in Lateral Flow Assays, 28% by 2034, against 11.62% growth in Molecular/PCR-based POC taking it from 15% to 20%. Its 27% weight in Europe means those movements carry straight into the regional totals. Germany carries its own technology breakdown in the full report.

In Germany, point of care diagnostic products are governed by the EU In Vitro Diagnostic Regulation, enforced domestically through the Federal Institute for Drugs and Medical Devices alongside notified bodies authorised to assess conformity. The regulation introduced a risk-based classification system that places most point of care tests under scrutiny proportional to the clinical consequence of an incorrect result, with higher-risk categories requiring notified body involvement rather than manufacturer self-certification alone. Suppliers must demonstrate conformity with applicable harmonised standards, compile technical documentation supporting analytical and clinical performance, and affix the CE marking before a device reaches the German market. Post-market surveillance obligations, including vigilance reporting, continue once the product is in circulation, and labelling must clearly state intended use, storage conditions, and any operator restrictions.

The suppliers tracked in this study (F. Hoffmann-La Roche Ltd., Danaher, BD, Qiagen, Abbott, Siemens Healthcare AG, bioMerieux SA, Zoetis, Inc., Instrumentation Laboratory, Nova Biomedical, Quidel Corp., Trividia Health, Inc., Sekisui Diagnostics, Nipro Corp., Trinity Biotech, Orasure Technologies, Inc. and Spectral Medical, Inc.) compete in Germany across the technology lines above. Lateral Flow Assays, at 34% of 2025 revenue, is where the volume sits, and Molecular/PCR-based POC, growing at 11.62%, is where position changes hands over the forecast period. A supplier weighted toward Europe is competing over a base of USD 6.84 billion in 2025 reaching USD 12.48 billion by 2034, 24% of global revenue at the start of that period.

5.26% of global revenue is generated in the United Kingdom; USD 1.5 billion in 2025, reaching USD 2.75 billion in 2034, and 22% of Europe.

France is sized at USD 1.23 billion in 2025, rising to USD 2.25 billion by 2034; 4.32% of global revenue and 18% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

USD 7.41 billion of 2025 revenue is generated in Asia Pacific, 26% of the global point of care diagnostic market and reaches USD 18.17 billion by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

Its share rises to 32% over the forecast period, so the region grows faster than the market's 8.21% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Segment composition follows the global pattern: Lateral Flow Assays largest at 34% of 2025 revenue, Molecular/PCR-based POC fastest at 11.62%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

China is the largest market within Asia Pacific, generating USD 2.52 billion in 2025 and projected to reach USD 6.18 billion by 2034. 34% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 7.41 billion to USD 18.17 billion over the same period, and this is the market carrying the country-level detail in the full report.

China buys along the same lines as the market globally; Lateral Flow Assays first at 34% of 2025 revenue and 28% in 2034, Molecular/PCR-based POC fastest at 11.62% on a share moving from 15% to 20%. With 34% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by technology for China is reported separately in the full report.

Point of care diagnostic products entering China are regulated by the National Medical Products Administration, which classifies in vitro diagnostic devices according to the risk they present to users and patients. Lower-risk tests may proceed through a registration pathway administered at the provincial level, while higher-risk categories require review and approval directly by the national authority, often supported by clinical evaluation data generated within the country. Imported devices typically need a local agent responsible for regulatory liaison and post-market obligations, and manufacturers must ensure Chinese-language labelling that accurately reflects intended use and handling requirements. Conformity with recognised national standards for manufacturing quality and product performance is also expected, and registration must be renewed periodically to remain valid for continued sale.

The suppliers tracked in this study (F. Hoffmann-La Roche Ltd., Danaher, BD, Qiagen, Abbott, Siemens Healthcare AG, bioMerieux SA, Zoetis, Inc., Instrumentation Laboratory, Nova Biomedical, Quidel Corp., Trividia Health, Inc., Sekisui Diagnostics, Nipro Corp., Trinity Biotech, Orasure Technologies, Inc. and Spectral Medical, Inc.) compete in China across the technology lines above. Two different problems sit on the same axis: holding Lateral Flow Assays at 34% of 2025 revenue, and taking Molecular/PCR-based POC while it grows at 11.62%. The commercial size of that position is USD 7.41 billion in 2025, moving to USD 18.17 billion by 2034 across the forecast period.

Within Asia Pacific, Japan accounts for 22% of regional revenue and 5.72% of the global total, worth USD 1.63 billion in 2025 and USD 4 billion by 2034.

India is sized at USD 1.19 billion in 2025, rising to USD 2.91 billion by 2034; 4.18% of global revenue and 16% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

USD 1.71 billion of 2025 revenue is generated in Latin America, 6% of the global point of care diagnostic market and reaches USD 3.4 billion by 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

Share settles at 6% in 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

The technology mix reported at global level applies here, with Lateral Flow Assays the largest line at 34% of 2025 revenue and Molecular/PCR-based POC the fastest-growing at 11.62%. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.

The largest single market in Latin America is Brazil, at USD 0.77 billion in 2025 and USD 1.53 billion in 2034. Its 45% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Against regional totals of USD 1.71 billion in 2025 and USD 3.4 billion in 2034, it is the country the full report breaks out in detail.

The technology pattern in Brazil is the global one: 34% of 2025 revenue in Lateral Flow Assays, 28% by 2034, against 11.62% growth in Molecular/PCR-based POC taking it from 15% to 20%. Since 45% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Brazil carries its own technology breakdown in the full report.

Point of care diagnostic devices sold in Brazil are regulated by the National Health Surveillance Agency, known locally as Anvisa, which oversees the registration of in vitro diagnostic products before they may be marketed. The agency applies a risk-based classification approach that determines the depth of technical review a product undergoes, with tests intended for use outside conventional laboratory settings assessed for both analytical reliability and the practical conditions under which non-specialist operators would use them. Manufacturers or their Brazilian representatives must submit technical dossiers demonstrating safety and performance, comply with good manufacturing practice requirements, and provide labelling in Portuguese that clearly states intended use and any operational limitations. Registration must remain current, and products are subject to ongoing post-market monitoring once authorised for sale.

In Brazil the field is F. Hoffmann-La Roche Ltd., Danaher, BD, Qiagen, Abbott, Siemens Healthcare AG, bioMerieux SA, Zoetis, Inc., Instrumentation Laboratory, Nova Biomedical, Quidel Corp., Trividia Health, Inc., Sekisui Diagnostics, Nipro Corp., Trinity Biotech, Orasure Technologies, Inc. and Spectral Medical, Inc.. The commercially relevant division is 34% of 2025 revenue in Lateral Flow Assays, where the volume is, against 11.62% growth in Molecular/PCR-based POC, where share moves. The commercial size of that position is USD 1.71 billion in 2025, moving to USD 3.4 billion by 2034 across the forecast period.

Mexico is sized at USD 0.51 billion in 2025, rising to USD 1.02 billion by 2034; 1.79% of global revenue and 30% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

6% of the global point of care diagnostic market sits in Middle East and Africa in 2025, worth USD 1.71 billion on the way to USD 3.4 billion by 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.

Share settles at 6% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

Segment composition follows the global pattern: Lateral Flow Assays largest at 34% of 2025 revenue, Molecular/PCR-based POC fastest at 11.62%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.

The largest single market in Middle East and Africa is Saudi Arabia, at USD 0.51 billion in 2025 and USD 1.02 billion in 2034. 30% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 1.71 billion to USD 3.4 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Lateral Flow Assays at 34% of 2025 revenue, easing to 28% by 2034, and the fastest is Molecular/PCR-based POC at 11.62%, from 15% to 20%. Because the country carries 30% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by technology for Saudi Arabia is reported separately in the full report.

In Saudi Arabia, point of care diagnostic devices fall under the authority of the Saudi Food and Drug Authority, which maintains a medical device registration system aligned in structure with international regulatory practice. Products are classified according to risk, and manufacturers or their authorised local representatives must submit registration applications supported by evidence of conformity assessment, often referencing approvals already granted by a recognised foreign regulator as part of the review. Establishment licensing is required for the local entity responsible for importing and distributing the device, and labelling must be provided in Arabic alongside the original language, stating intended use and handling instructions clearly. Ongoing compliance includes adverse event reporting and maintaining registration validity for as long as the product remains on the market.

In Saudi Arabia the field is F. Hoffmann-La Roche Ltd., Danaher, BD, Qiagen, Abbott, Siemens Healthcare AG, bioMerieux SA, Zoetis, Inc., Instrumentation Laboratory, Nova Biomedical, Quidel Corp., Trividia Health, Inc., Sekisui Diagnostics, Nipro Corp., Trinity Biotech, Orasure Technologies, Inc. and Spectral Medical, Inc.. The commercially relevant division is 34% of 2025 revenue in Lateral Flow Assays, where the volume is, against 11.62% growth in Molecular/PCR-based POC, where share moves. The commercial size of that position is USD 1.71 billion in 2025 and USD 3.4 billion by 2034, 6% of the global total in the base year.

1.33% of global revenue is generated in South Africa; USD 0.38 billion in 2025, reaching USD 0.75 billion in 2034, and 22% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by technology, product, end-use, sample type, distribution channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.